- Trial will evaluate the efficacy and safety of Novartis targeted therapy TABRECTA® and Pumas NERLYNX® in patients with metastatic HER2-negative breast cancer selected by Celcuitys CELsignia Multi-Pathway Activity Test
- This is Celcuitys second clinical trial to treat patients diagnosed with hyperactive HER2 and c-Met signaling breast cancers with matching targeted therapies
- Five clinical trial collaborations are now in place and include ones with Genentech, Pfizer, Novartis and Puma
MINNEAPOLIS--(BUSINESS WIRE)-- Celcuity Inc. (Nasdaq: CELC), a clinical stage biotechnology... More